Osteomark gets boost from Merck's Fosamax:
This article was originally published in Clinica
US approval on October 2nd of Merck & Co's nonhormonal treatment for osteoporosis in post-menopausal women has been welcomed by Ostex which produces Osteomark, the first commercially available test to measure bone resorption. Trial data show that the Ostex test has potential use in monitoring patients' response to Fosamax therapy, says Dr B Gertz of Merck Research Laboratories and a member of the Ostex scientific advisory board.
You may also be interested in...
GNC hires Josh Burris as chief US officer; Clasado BioSciences adds Bellchambers as commercial director; and Barentz plans expansion with Cinven investment.
The House passage of a Democratic bill authorizing the federal government to negotiate drug prices in Medicare has sharpened the debate over how prices feed innovation, but the underlying policy stands little chance of being enacted without a Democratic wave in the next election. Pink Sheet's table highlights the key provisions of HR 3 and other pending pricing legislation.